RUSNANO was founded as a joint stock company in March 2011, through reorganization of state corporation Russian Corporation of Nanotechnologies. RUSNANO is instrumental in realizing government policies for nanoindustry growth, investing in financially effective high-technology projects that guarantee the development of new manufacturing within the Russian Federation. The company invests in nanotechnology companies directly and through investment funds. Its primary investment focus is in electronics, optoelectronics and telecommunications, healthcare and biotechnology, metallurgy and metalwork, energy, mechanical engineering and instrument making, construction and industrial materials, chemicals and petrochemicals. The Government of the Russian Federation owns 100 percent of the shares in RUSNANO. By the moment thanks to RUSNANO’s investments 73 plants and R&D centers are launched in 32 regions of Russia.

Management of the investment assets of RUSNANO are carried out by a limited liability company established in December 2013, RUSNANO Asset Management. Anatoly Chubais is Chairman of its Executive Board.

Media Center

  • 22 March 2018

    GMP Inspection practice: a case for global benchmarking, convergence and mutual reliance/recognition

    In 1969 the global agreement on the Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce was proposed by WHO. The aim was to facilitate international trade in pharmaceuticals through mutual recognition of GMP inspection results. Today, almost 50 years later, up to one hundred countries conduct foreign inspections. As a result a manufacturing site well established, might be inspected  many times in one year by local and different foreign authorities. This leads to duplication of work and waste of recourses both by regulators and industry.

  • 22 March 2018

    Kaluga is expected to complete its program for radiopharmaceuticals in two years

    Kaluga pharmaceutical cluster recently increased the number of locally manufactured drugs from 65 to 154. The Governor Anatoly Artamonov expects that the region needs 2 more years to complete its import substitution program for radiopharmaceuticals, reported Kaluzhskaya Nedelya, a local newspaper.

  • 21 March 2018

    Blockchain technology has a special potential to confront counterfeit drugs

    DHL has released a trend report in cooperation with Accenture, a leading global technology consultant, on blockchain technology’s potential to transform the logistics industry. The report includes initial findings on a working prototype developed by DHL and Accenture, which tracks pharmaceuticals from the point of origin to the consumer, preventing tampering and errors.

  • 20 March 2018

    Russia establishes its National Quality Infrastructure Council

    On March 14, Denis Manturov, the Russian Minister of Industry and Trade, chaired a meeting of the State Commission on Counteraction to Illegal Circulation of Industrial Products. The Minister said that, ensuring the “market purity” would require, in addition to providing more preferences for entrepreneurs operating strictly within the legal field, to guarantee to potential consumers that they purchase genuine rather than counterfeit and falsified products.

Read more